Recent Investment Analysts’ Ratings Updates for aTyr Pharma (ATYR)

A number of firms have modified their ratings and price targets on shares of aTyr Pharma (NASDAQ: ATYR) recently:

• 9/15/2025 – aTyr Pharma was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating.
• 9/15/2025 – aTyr Pharma was downgraded by analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating.
• 9/15/2025 – aTyr Pharma had its “market perform” rating reaffirmed by analysts at Leerink Partners.
• 9/15/2025 – aTyr Pharma was downgraded by analysts at Jones Trading from a “strong-buy” rating to a “hold” rating.
• 9/15/2025 – aTyr Pharma was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 9/15/2025 – aTyr Pharma had its “equal weight” rating reaffirmed by analysts at Wells Fargo & Company.
• 8/22/2025 – aTyr Pharma had its price target raised by analysts at Jefferies Financial Group Inc. from $9.00 to $17.00. They now have a “buy” rating on the stock.
• 8/9/2025 – aTyr Pharma was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.